Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended
release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80
mg IR, respectively, in participants with gout.